Carina Namih moved from studying Politics, Philosophy and Economics at Oxford into building HelixNano, an RNA biotech company, without the usual lab spinout or pharma pedigree, and later stepped from CEO to board member while staying committed to its mission. That experience shapes how she invests today: she looks for founders spotting deep technical or behavioral shifts early, favors giving minimal but essential input rather than generic advice, and gravitates toward fields like robotics and embodied AI where hardware, software, and real-world conditions finally align.